

PAR/CS/NSE/2023-24/08

To,

The Manager

Listing department,

**National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block-G,

Bandra Kurla Complex, Bandra (E),

Mumbai- 400 051

Maharashtra

**Date:27/04/2023**

Subject: Disclosure of Related Party Transaction pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements), 2015

Ref.: **Symbol- PAR, ISIN: INE04LG01015**

Dear Sir/Madam,

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements), 2015, please find enclosed herewith disclosure of Related Party Transaction on standalone basis for the Second half year ended 31<sup>st</sup> March, 2023 in the format as specified in the Circular SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021 by SEBI.


Kindly take on the record and acknowledge the receipt.

Yours Faithfully,

**For PAR DRUGS AND CHEMICALS LIMITED**

\_\_\_\_\_  
(Sanket B. Trivedi)

Company Secretary & Compliance Officer



Encl: As above

### Related party transactions

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

Sr No.	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments						Notes
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment )	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)		
<div><div>Add</div><div>Delete</div></div>																							
1	Par Drugs And Chemicals Limited		Falgunbhai V Savani		Managing Director	Remuneration			Nil	25.75	16.03	2.79									Textual information(1)		
2	Par Drugs And Chemicals Limited		Falgunbhai V Savani		Managing Director	Any other transaction	Director Sitting Fees		Nil	2.00	0.00	0.00									Textual information(2)		
3	Par Drugs And Chemicals Limited		Falgunbhai V Savani		Managing Director	Any other transaction	Re-imbusement of Expenses		Nil	0.48	0.00	0.00									Textual information(3)		
4	Par Drugs And Chemicals Limited		Jigneshbhai V Savani		CEO	Remuneration			Nil	25.75	27.27	3.09									Textual information(4)		
5	Par Drugs And Chemicals Limited		Jigneshbhai V Savani		CEO	Any other transaction	Director Sitting Fees		Nil	0.10	0.00	0.00									Textual information(5)		
6	Par Drugs And Chemicals Limited		Ghanshyambhai B Savani		Whole-Time Director	Remuneration			Nil	25.75	27.71	3.19									Textual information(6)		
7	Par Drugs And Chemicals Limited		Ghanshyambhai B Savani		Whole-Time Director	Any other transaction	Director Sitting Fees		Nil	0.10	0.00	0.00									Textual information(7)		
8	Par Drugs And Chemicals Limited		Sanket Bhupendrabhai Trivedi		Company Secretary	Remuneration			Nil	3.60	0.43	0.43									Textual information(8)		
9	Par Drugs And Chemicals Limited		Chintan Pratapbhai Chauhan		Chief Financial Officer	Remuneration			Nil	3.19	0.36	0.36									Textual information(9)		
10	Par Drugs And Chemicals Limited		Naynaben J Savani		Non-Executive Director	Any other transaction	Director Sitting Fees		Nil	0.15	0.25	0.00									Textual information(10)		
11	Par Drugs And Chemicals Limited		Kajal Chitanbhai Vaghani		Independent Director	Any other transaction	Director Sitting Fees		Nil	0.25	0.20	0.05									Textual information(11)		
12	Par Drugs And Chemicals Limited		Krishna Mitulbhai Shah		Independent Director	Any other transaction	Director Sitting Fees		Nil	4.00	0.31	0.05									Textual information(12)		
13	Par Drugs And Chemicals Limited		Pravin Manjibhai Bhayani		Independent Director	Any other transaction	Director Sitting Fees		Nil	0.40	0.31	0.05									Textual information(13)		
14	Par Drugs And Chemicals Limited		Bintal Bhaveshkumar Shah		Independent Director	Any other transaction	Director Sitting Fees		Nil	0.15	0.10	0.05									Textual information(14)		
Total value of transaction during the reporting period											91.668348												

## Text Block

Textual Information(1)	By considering recommendations of Audit Committee & Nomination and Remuneration Committee , the Board at its meeting held on 24th August, 2021 approved increase in remuneration of respective director for a period of 2 years from 26th Day of November, 2021 to 25th Day of November, 2023, Subsequently the same is approved by the shareholders in the Twenty Second (22nd )Annual General Meeting (AGM) of the Members of Par Drugs And Chemicals Limited which was held on Wednesday, 29th Day of September, 2021
Textual Information(2)	By considering recommendations of Audit Committee and Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(3)	By considering recommendations of Audit Committee & Nomination and Remuneration Committee , the Board at its meeting held on 24th August, 2021, approved for a period of 2 years from 26th Day of November, 2021 to 25th Day of November, 2023, Subsequently the same is approved by the shareholders in the Twenty Second (22nd )Annual General Meeting (AGM) of the Members of Par Drugs And Chemicals Limited which was held on Wednesday, 29th Day of September, 2021
Textual Information(4)	By considering recommendations of Audit Committee & Nomination and Remuneration Committee , the Board at its meeting held on 24th August, 2021 approved increase in remuneration of respective director for a period of 2 years from 26th Day of November, 2021 to 25th Day of November, 2023, Subsequently the same is approved by the shareholders in the Twenty Second (22nd )Annual General Meeting (AGM) of the Members of Par Drugs And Chemicals Limited which was held on Wednesday, 29th Day of September, 2021
Textual Information(5)	By considering recommendations of Audit Committee and Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(6)	By considering recommendations of Audit Committee & Nomination and Remuneration Committee , the Board at its meeting held on 24th August, 2021 approved increase in remuneration of respective director for a period of 2 years from 26th Day of November, 2021 to 25th Day of November, 2023, Subsequently the same is approved by the shareholders in the Twenty Second (22nd )Annual General Meeting (AGM) of the Members of Par Drugs And Chemicals Limited which was held on Wednesday, 29th Day of September, 2021
Textual Information(7)	By considering recommendations of Audit Committee and Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(8)	
Textual Information(9)	
Textual Information(10)	By considering recommendations of Audit Committee and Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(11)	By considering recommendations of Audit Committee and Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(12)	By considering recommendations of Audit Committee and Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(13)	By considering recommendations of Audit Committee and Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(14)	By considering recommendations of Audit Committee and Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.